LB-4. Cefepime-Enmetazobactam Demonstrates Superiority to Piperacillin-Tazobactam in a Subgroup of Patients with Complicated Urinary Tract Infections/Acute Pyelonephritis Caused by Extended Spectrum β-Lactamase-Producing Enterobacterales

BACKGROUND: There is a critical need for carbapenem-sparing therapies for infections caused by extended spectrum β-lactamase (ESBL)-producing Enterobacterales. Enmetazobactam is a novel ESBL inhibitor combined with the cephalosporin cefepime. Treatment outcomes of cefepime-enmetazobactam (FPE) versu...

Descripción completa

Detalles Bibliográficos
Autores principales: Belley, Adam, Barth, Philip, Kashyap, Shikhar, Lahlou, Omar, Motta, Paola, Knechtle, Philipp, Velicitat, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Late Breaker Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776372/
http://dx.doi.org/10.1093/ofid/ofaa515.1901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776372/
http://dx.doi.org/10.1093/ofid/ofaa515.1901

Ejemplares similares